Baranick Brian, General Manager of Precision Oncology, has demonstrated a clear selling bias in his trading activity involving Exact Sciences Corporation (EXAS), as reflected in SEC Form 4 filings. Over 34 reported transactions, all activity has been concentrated in EXAS, with no recorded purchases and total sales exceeding $9.32 million. The most significant disposals occurred in late December 2025, with seven separate transactions on December 23 alone, totaling approximately $6.96 million. These included sales of $2.20 million, $1.49 million, and $1.06 million, alongside smaller dispositions ranging from $204,556 to $829,935. Earlier that month, on December 24, another $1.52 million sale was executed.
More recent activity includes two smaller sales: a $200,289 transaction on November 4, 2025, and a $127,237 sale on August 5, 2025. The earliest recorded sale dates back to March 1, 2024, at $137,800. Notably, several filings in 2026—marked as derivative transactions (Code D) and acquisitions (Code A)—show no monetary value, suggesting non-cash adjustments to holdings rather than open-market trades. The pattern indicates a consistent reduction in Brian’s EXAS position over nearly two years, with the bulk of monetization occurring in late 2025. The absence of any buying activity during this period reinforces a one-directional trend toward divestment.
AI-assisted summary